Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep
growing. Goserelin may interfere with the growth factor and may stop the tumor from growing.
Bicalutamide may prevent androgens from stimulating the growth of cancer cells.
PURPOSE: Phase II trial to study the effectiveness of goserelin plus bicalutamide in treating
patients who have refractory or recurrent cancer of the ovary, fallopian tube, or peritoneum.